double-skinned crabsVietnamese crab exporter
Advertisement
Advertisement
TOPIC

Biomedicine: Industry Trends

Related Topics:
Biomedicine: Industry Trends
Learn about China’s biomedical breakthroughs, from cutting-edge pharmaceuticals to life-saving research, driving global health innovation.
China’s biotech sector has shifted from speed-driven replication to differentiated innovation, according to analysts. Photo: Shutterstock
Mainland China

How Chinese biotech is graduating from licensing deals to broader partnerships

InnoCare’s pact with Eli Lilly, potentially worth up to US$3.35 billion, highlights a shift towards bigger partnerships, analysts say.

China technology

Are clinical trials about to become a new front in the US-China biotech race?

Hong Kong stock market

‘High tide’ of China biotech deals seen as US curb fears fade: analysts

videocam
China economy

China’s five-year plan for pharmaceuticals and biomedicine

China aims to become a global drug powerhouse by 2030, according to its five-year development plan for the pharmaceutical and biomedicine sector.

Photo: Xinhua
Biomedicine: Policy

Can targeted sound waves transform treatment for pancreatic and brain cancers?

A leading advocate says global trials in pancreatic and brain cancers may yield results within 3 years, with Alzheimer’s another application.

Biomedicine: Policy

Biomedicine powerhouse: China targets quarter of global first-in-class drugs

New five-year plan aims to turn the sector into a pillar industry by 2030, driven by breakthroughs in technologies across critical fields.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

ByteDance spin-off Anew Labs raises US$290m amid AI drug design fundraising boom

As AI’s role in drug design advances rapidly, Chinese start-ups are ramping up fundraising efforts.

videocam
AI is increasingly being used in the design of novel drugs. Photo: Shutterstock Images
Biomedicine: Companies

GSK’s US$750 million cancer drug deal highlights China’s rise as biotech player

The acquisition is the latest in a string of major licensing deals involving Chinese biotechnology firms.

4
Greater Bay Area

Data from Greater Bay Area residents to help improve healthcare policy: GSK

Executive says pharmaceutical company is investing in shared data infrastructure.

Yuan

Open Questions | Private equity’s Fang Fenglei on investing in China

Veteran investor considers China’s economic strengths, assets that appeal, future yuan appreciation and policymakers’ ability to solve problems.

videocam
Illustration: Brian Wang
Greater Bay Area

Hong Kong targets biomedicine powerhouse status in debut 5-year plan

Tied to the national strategy, the city’s first five-year blueprint doubles down on Greater Bay Area medical tech and healthcare cooperation.

Hong Kong Secretary for Health Lo Chung-mau speaking at the fifth Hong Kong International Biotechnology Conference and Exhibition. Photo: Handout
China’s private sector

China needs monkeys: lab animal shortage could hinder biotech growth

As fundraising and out-licensing deals in China grow, so does demand for monkeys and other primates for testing.

Science

US, China trials suggest a single nanodrug shot might stop bad cholesterol forever

Separate trials using CRISPR and base editing to silence lipid genes show drastic drops in LDL-C without daily medication.

videocam
IPO

More Chinese developers of brain-computer interfaces move towards IPOs

Arfysica and Neuracle aim for Star Market listings amid what a Morgan Stanley analyst calls the ‘early stage of a multi-year IPO upcycle’.

videocam
The firms join a broader trend of hi-tech firms flocking to the Shanghai Stock Exchange’s Nasdaq-style Star Market. Photo: Xinhua
China technology

China approves string of ‘telepathy’ devices amid push to leapfrog Elon Musk

Chinese regulators have approved a group of brain-technology products this year, as local start-ups push to surpass Musk’s Neuralink.

Domestically developed brain-computer interface products at China Sensor Valley in Bengbu, Anhui province, last month. Photo: Xinhua
Banking & finance

Why Asian investors are pouring capital into brain tech and surgical robots

Family offices and venture investors across Hong Kong and the wider region are reshaping portfolios to capture long-term biotech growth.

Banking & finance

US surgical robotics firm targets Hong Kong listing to tap mainland China market

Noah Medical expects to file application as early as next year, joining surge of tech listings tapping city’s international fundraising pool.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong stock market

China’s Akeso says cancer drug beat AstraZeneca’s Imfinzi in phase 3 trial

The biliary tract cancer trial is the latest breakthrough for Akeso’s ivonescimab, which has also shown promise in treating some lung cancers.

China’s biopharmaceutical firms are increasingly looking to compete directly on the global market. Photo: Shutterstock
Robotics

Brain-tech push gains pace as China sets standards and firms challenge Neuralink

Dozens of guidelines are coming, covering medical, industrial and consumer users as emerging neural technology moves towards wider adoption.

4
Hong Kong stock market

China rushes to develop Moderna-style cancer vaccines amid market frenzy

Chinese biotech firms are already working on more than 100 cancer vaccines. Now, many are seeing their shares surge amid Moderna’s breakthrough.

videocam
7
Wuxi Biologics

WuXi Biologics posts 4.3% rise in first-half profit, defying biotech headwinds

Higher gross margins, surging projects and continued demand from North American markets help power the drug developer’s strong first-half performance.

Wuxi Biologics is a pharmaceutical research and services company based in Wuxi, Jiangsu province, China. Photo: Shutterstock
Medicine

Overseas licensing has helped fuel China’s biotech profits. Will it last?

Out-licensing deals have overtaken IPOs as the primary lifeline for cash-starved Chinese drug makers, analysts say.

videocam
Asset id: 2156561481 Cross-border out-licensing deals are proving profitable for Chinese drugmakers. Photo: Shutterstock Images
Science

Chinese stem cell therapy restores heart function in 90% of trial patients

Study finds patients injected with iPSC-derived heart muscle cells outperform control group on cardiac function tests after bypass surgery.

videocam
12
Mainland China

Video | Chinese scientists develop ‘smart’ diabetes probiotic

The lab-engineered probiotic, named Gift, can sense high blood sugar and automatically release the glucose-lowering hormone GLP-1.

Hong Kong economy

Editorial | Hong Kong is stepping up its contribution to global healthcare

The Global Health Summit highlighted the city’s potential to become an elite international hub for biomedicine and biotechnology.

Clara Chan, CEO of Hong Kong Investment Corporation, speaks at the Global Health Summit at the Hong Kong Convention and Exhibition Centre on August 7. Photo: Jonathan Wong
Stanford University

Patience needed before human gene therapy trials, Stanford expert says

Human testing could take up to five years to ramp up, but AI approaches will yield results in time, Karoly Nikolich says.

videocam
Karoly Nikolich, pictured at the Hong Kong Convention and Exhibition Centre on August 8. Photo: Edmond So
China technology

The next tech race? China launches push to leapfrog US in ‘brain chip’ devices

China is throwing the power of the state behind efforts to overtake Elon Musk in a vital frontier technology: brain-computer interfaces.

14
China’s private sector

China’s drug firms set to compete on the world stage, analysts say

Amid systemic efficiency and a wave of innovation, the country’s biotech sector is expanding at a pace that has caught the market off guard.

4
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement